S&P 500   3,788.66 (+0.14%)
DOW   30,270.33 (-0.01%)
QQQ   282.26 (+0.10%)
AAPL   146.96 (+0.38%)
MSFT   250.12 (+0.37%)
META   139.07 (+0.06%)
GOOGL   102.58 (+1.13%)
AMZN   121.21 (+0.21%)
TSLA   242.41 (+0.66%)
NVDA   135.43 (+2.53%)
NIO   16.01 (-0.19%)
BABA   84.92 (+0.63%)
AMD   69.83 (+2.78%)
T   15.77 (-1.00%)
MU   55.05 (+0.58%)
CGC   3.13 (+1.95%)
F   12.50 (-0.08%)
GE   67.27 (-0.25%)
DIS   100.96 (+0.16%)
AMC   7.49 (+2.18%)
PYPL   94.55 (+0.77%)
PFE   43.67 (-1.02%)
NFLX   238.67 (+0.82%)
S&P 500   3,788.66 (+0.14%)
DOW   30,270.33 (-0.01%)
QQQ   282.26 (+0.10%)
AAPL   146.96 (+0.38%)
MSFT   250.12 (+0.37%)
META   139.07 (+0.06%)
GOOGL   102.58 (+1.13%)
AMZN   121.21 (+0.21%)
TSLA   242.41 (+0.66%)
NVDA   135.43 (+2.53%)
NIO   16.01 (-0.19%)
BABA   84.92 (+0.63%)
AMD   69.83 (+2.78%)
T   15.77 (-1.00%)
MU   55.05 (+0.58%)
CGC   3.13 (+1.95%)
F   12.50 (-0.08%)
GE   67.27 (-0.25%)
DIS   100.96 (+0.16%)
AMC   7.49 (+2.18%)
PYPL   94.55 (+0.77%)
PFE   43.67 (-1.02%)
NFLX   238.67 (+0.82%)
S&P 500   3,788.66 (+0.14%)
DOW   30,270.33 (-0.01%)
QQQ   282.26 (+0.10%)
AAPL   146.96 (+0.38%)
MSFT   250.12 (+0.37%)
META   139.07 (+0.06%)
GOOGL   102.58 (+1.13%)
AMZN   121.21 (+0.21%)
TSLA   242.41 (+0.66%)
NVDA   135.43 (+2.53%)
NIO   16.01 (-0.19%)
BABA   84.92 (+0.63%)
AMD   69.83 (+2.78%)
T   15.77 (-1.00%)
MU   55.05 (+0.58%)
CGC   3.13 (+1.95%)
F   12.50 (-0.08%)
GE   67.27 (-0.25%)
DIS   100.96 (+0.16%)
AMC   7.49 (+2.18%)
PYPL   94.55 (+0.77%)
PFE   43.67 (-1.02%)
NFLX   238.67 (+0.82%)
S&P 500   3,788.66 (+0.14%)
DOW   30,270.33 (-0.01%)
QQQ   282.26 (+0.10%)
AAPL   146.96 (+0.38%)
MSFT   250.12 (+0.37%)
META   139.07 (+0.06%)
GOOGL   102.58 (+1.13%)
AMZN   121.21 (+0.21%)
TSLA   242.41 (+0.66%)
NVDA   135.43 (+2.53%)
NIO   16.01 (-0.19%)
BABA   84.92 (+0.63%)
AMD   69.83 (+2.78%)
T   15.77 (-1.00%)
MU   55.05 (+0.58%)
CGC   3.13 (+1.95%)
F   12.50 (-0.08%)
GE   67.27 (-0.25%)
DIS   100.96 (+0.16%)
AMC   7.49 (+2.18%)
PYPL   94.55 (+0.77%)
PFE   43.67 (-1.02%)
NFLX   238.67 (+0.82%)
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$9.26
+0.11 (+1.20%)
(As of 10/6/2022 09:38 AM ET)
Add
Compare
Today's Range
$9.14
$9.29
50-Day Range
$8.34
$12.91
52-Week Range
$6.85
$47.13
Volume
530 shs
Average Volume
1.09 million shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.08

NeoGenomics MarketRank™ Forecast

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
119.4% Upside
$20.08 Price Target
Short Interest
Healthy
3.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of NeoGenomics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

133rd out of 1,072 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics, Inc. (NASDAQ: NEO)
Here’s How Artisan Partners Views NeoGenomics (NEO)
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $20.10
NeoGenomics: Q2 Earnings Insights - Benzinga
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.08
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+116.8%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$-8,350,000.00
Pretax Margin
-33.02%

Debt

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.19 per share
Book Value
$9.00 per share

Miscellaneous

Free Float
124,538,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.96

Key Executives

  • Mr. George A. CardozaMr. George A. Cardoza (Age 60)
    Pres & COO of Lab Operations
    Comp: $800.5k
  • Ms. Kathryn B. McKenzieMs. Kathryn B. McKenzie (Age 38)
    Chief Sustainability & Risk Officer
    Comp: $793.48k
  • Mr. Christopher Michael Smith BSc (Age 59)
    CEO & Director
  • Mr. William Bishop Bonello (Age 57)
    Chief Financial Officer
  • Ms. Cynthia J. Dieter (Age 47)
    Chief Accounting Officer
  • Mr. John Mooney
    Chief Technology Officer
  • Dr. Shashikant Kulkarni Facmg
    M.B.A., M.S., Ph.D., Pres of Lab Operations & Chief Scientific Officer
  • Charlie Eidson
    Director of Investor Relations and Corp. Devel.
  • Mr. Hutan Hashemi J.D.
    Chief Compliance Officer
  • Mr. Marcus B. Silva J.D. (Age 46)
    M.B.A., Chief Marketing Officer













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEO, but not buy additional shares or sell existing shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2022?

11 analysts have issued 12 month price targets for NeoGenomics' stock. Their NEO share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $20.08 in the next year. This suggests a possible upside of 119.4% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2022?

NeoGenomics' stock was trading at $34.12 at the start of the year. Since then, NEO shares have decreased by 73.2% and is now trading at $9.15.
View the best growth stocks for 2022 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, August, 9th. The medical research company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. The medical research company had revenue of $125 million for the quarter, compared to analyst estimates of $123.26 million. NeoGenomics had a negative net margin of 30.00% and a negative trailing twelve-month return on equity of 8.53%. The company's revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Moody National Bank Trust Division (0.01%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $9.15.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.15 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,000 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.